Navigation Links
Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119
Date:9/21/2009

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will be hosting a conference call to discuss today's announcement of a new partnership for NKTR-118 and NKTR-119. The call will begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT).

The live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page of Nektar's website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, October 19, 2009.

        To access the conference call, follow these instructions:

        Dial: (866) 543-6403 (U.S.); (617) 213-8896 (international)
        Passcode: 72093106 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Monday, October 19, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 36361745.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
2. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
3. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
5. Nektar Therapeutics Reports First Quarter 2009 Financial Results
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
7. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Announces Retirement of Irwin Lerner from Board of Directors
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
11. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
(Date:4/20/2017)...  Eli Lilly and Company (NYSE: LLY ... the prevention of migraine at the American Academy of ... 22-28, 2017, in Boston . ... including safety and patient outcomes data for galcanezumab in ... in monthly migraine headache days among patients with episodic ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... and clinical research community’s growing body of knowledge during its Eighth Annual ... Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, and ...
(Date:4/20/2017)... 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: ... the International Liver Congress ("ILC") 2017 of the European Association ... Amsterdam on the positive effects of PBI-4050 on ... obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):